Gene test could guide chemo choice for tough pancreatic cancer

NCT ID NCT05475366

Recruiting now Knowledge-focused Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 23 times

Summary

This study aims to see if using genetic signatures from a liver biopsy can help doctors choose the most effective first chemotherapy for people with advanced pancreatic cancer. About 85 participants will have their treatment selected based on these genetic tests, and researchers will measure how well the cancer responds. The goal is to improve response rates and personalize care for this difficult-to-treat disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

CHU Robert Debré
RECRUITING

Reims, 51092, France

Contact
Hôpital Beaujon
RECRUITING

Clichy, 92210, France

Contact
Hôpital Claude Hurriez
RECRUITING

Lille, 59037, France

Contact
Hôpital HENRI MONDOR
RECRUITING

Créteil, 94010, France

Contact
Hôpital PAUL BROUSSE 12 Avenue Paul Vaillant Couturier
RECRUITING

Villejuif, 94800, France

Contact
Institut Curie
RECRUITING

Saint-Cloud, 92210, France

Contact
Institut Paoli-Calmettes
RECRUITING

Marseille, 13573, France

Contact

Conditions

Explore the condition pages connected to this study.

CARCINOMA, PANCREATIC DUCTAL PROGNOSIS